Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Death Risk By 42%
Key takeaways
- Intismeran plus KEYTRUDA cuts melanoma recurrence or death risk by up to 58%, marking a major advance for personalized mRNA cancer therapy.
- 42% risk reduction in recurrence or death (HR 0.58, 95% CI 0.45–0.75)
- 58% risk reduction after six months (HR 0.42, 95% CI 0.30–0.58)
- 38% reduction in distant metastasis or death (HR 0.62, 95% CI 0.45–0.85)
What happened
Merck and Moderna announced that their joint mRNA cancer therapy, intismeran (V940 or mRNA‑4157), combined with the PD‑1 blocker KEYTRUDA, cut the risk of melanoma recurrence or death by 42% compared with KEYTRUDA alone in a Phase 3 trial of patients with completely resected stage IIB‑IV melanoma. The benefit was larger after the first six months of treatment, with a 58% reduction in risk (HR 0.42) in a sensitivity analysis. The combination also lowered the risk of distant metastasis or death…
Why it matters
The results demonstrate that a personalized mRNA neoantigen vaccine can meaningfully improve outcomes when added to standard immunotherapy for high‑risk melanoma. A 42‑58% risk reduction in recurrence or death is clinically significant and could change the standard of care for this patient group. The data were…
Short-term and longer-term
Short-term. Over the next few weeks, traders should watch for the ESMO presentation and the NEJM publication, which could prompt a price move.
Longer-term. For investors, the trial signals a potentially transformative addition to Merck’s oncology lineup and a new revenue stream for Moderna’s vaccine platform.